BIONEWS
KCL 286, an oral pill, eased brain cell DNA damage and inflammation in mouse studies. Its only human testing is an early safety trial for a different condition: spinal cord injury.
KCL-286, an experimental Alzheimer's drug from King's College London, leaves amyloid-beta plaques alone and instead repairs the upstream DNA damage and calms the neuroinflammation that appear earlier in the disease. In mouse studies, the molecule did both. The only human testing so far is a small safety trial for a different condition: spinal cord injury.
A 17 July 2026 release from King's College London and the corresponding paper in FEBS Open Bio describe KCL-286 as a first-in-class oral pill that activates a receptor called retinoic acid receptor-β, or RARβ, a protein that helps switch on a set of genes involved in nerve repair. First-in-class means it is the first drug of its kind to reach this stage of development. In the mouse work, the molecule reduced DNA damage in neurons and lowered brain inflammation, engaging several disease pathways at once.
The two most recently approved Alzheimer's drugs, lecanemab and donanemab, are antibodies that clear amyloid-beta from the brain and have shown measurable but limited slowing of cognitive decline in trials. Other programs target tau, a second protein that tangles inside dying neurons. KCL-286 is built around a different premise: that DNA damage accumulates in aging neurons and chronic neuroinflammation keeps the tissue hostile to new connections, and that acting on those processes earlier could slow the disease before plaques dominate.
KCL-286 was originally developed for spinal cord injury and has already cleared a Phase 1 safety trial in healthy male volunteers, the earliest human checkpoint, where the goal is mostly to confirm a drug is tolerated at expected doses. That clearance belongs to the spinal-cord-injury program, not to Alzheimer's. But the toxicology and dosing groundwork a first-in-class molecule normally needs from scratch is already in the bag.
The team, led by Professor Jonathan Corcoran at King's College London's Institute of Psychiatry, Psychology & Neuroscience, is now in the awkward middle distance of translational neuroscience: past mouse, past first-in-human safety, not yet in the patients the drug is aimed at. The next concrete watch item is whether the group files a Phase 1b or early Phase 2 trial in early Alzheimer's patients. Until then, the public record ends at the FEBS Open Bio paper, the KCL release, and the Phase 1 safety data.